Evvy is a precision women's health company that uses the vaginal microbiome to identify and apply overlooked female biomarkers across a woman's lifespan. Its technical work spans metagenomics, microbiome genomics, biomarker discovery, and artificial intelligence and machine learning, applied to precision medicine, diagnostics, and clinical validation.
The company's Vaginal Microbiome Test is a metagenomics-based assay analysing more than 700 bacteria and fungi; its validation was published in the peer-reviewed Diagnostics journal. Alongside it sits an AI-powered personalised care platform serving both providers and patients across vaginal symptoms, UTIs, fertility and menopause. The platform reaches over 100,000 patients and 3,000 providers nationwide in the United States, and the company holds a proprietary dataset described as the world's largest on the vaginal microbiome.
Engineering and research work is directed at data-driven breakthroughs in infertility, preterm birth and gynecological cancers. Findings are presented at major clinical conferences including ACOG, ASRM, IDSOG, ISSVD and ISSWSH, reflecting a research-oriented culture built around peer-reviewed validation. Evvy is backed by investors including General Catalyst, Left Lane Capital, US Fertility and Labcorp.
